The MedTech funding round will fuel Plexāā’s entry into the U.S. market with BLOOM⁴³, the world’s first fully wearable prehabilitation device for breast surgery designed to reduce complications.
UK-based MedTech innovator Plexāā has successfully closed a $4.5 million funding extension to support the U.S. commercial launch of its flagship medical device, BLOOM⁴³, a breakthrough wearable platform designed to improve outcomes in breast surgery.
This strategic funding round positions Plexāā for accelerated growth in the U.S. healthcare market and sets the stage for its upcoming Series A fundraising.
Led by TCP Health Ventures, with participation from Thena Capital, existing investors, and over $1.6 million in i4i grant funding from UK’s National Institute for Health and Care Research (NIHR), this extension brings Plexāā’s total seed funding to over $10 million.
The investment underscores strong investor confidence in Plexāā’s innovative surgical technology and its mission to revolutionize surgical prehabilitation through Supraphysiological Preconditioning™.
Innovative MedTech Funding for Surgical Outcomes
This MedTech funding round will fuel Plexāā’s entrance into the U.S. market with BLOOM⁴³, the world’s first fully wearable prehabilitation device for breast surgery.
Designed to reduce surgical complications such as infection, skin necrosis, and wound healing failure—which impact nearly 30% of breast surgery patients¹—BLOOM⁴³ uses a novel technique that leverages thermal therapy to improve skin vascularity and surgical readiness.
“Securing this funding validates confidence in our flagship technology and the concept of Supraphysiological Preconditioning™,” said Dr. Saahil Mehta, founder and CEO of Plexāā. “It energizes the team as we prepare to bring BLOOM⁴³ to a wider patient population in the U.S. and beyond.”
With the support of this latest startup funding round, Plexāā will expand its clinical partnerships, scale its U.S. operations, and continue development on its platform of wearable surgical technologies targeting additional specialties.
The BLOOM⁴³ Device: Redefining Surgical Prehabilitation
BLOOM⁴³ integrates a wearable device with a companion app, enabling patients to precondition their skin with intermittent, safe thermal stimulation. This Prehabilitation™ approach, backed by proof-of-concept clinical trials, has been shown to trigger the release of heat-shock proteins, which stimulate vasodilation and improve tissue health before surgery.
The goal? To prepare patients physically and psychologically before breast surgery—improving recovery times, reducing complications, and enhancing the patient experience.
With strategic partners already in place for the U.S. launch, BLOOM⁴³ is poised to make a significant impact in women’s health, addressing a long-overlooked segment of pre-surgical care.
Backed by Leading Health Investors
Plexāā’s funding success reflects growing investor enthusiasm for high-impact MedTech solutions targeting surgical optimization and digital health innovation.
“Tackling post-operative complications for breast surgery patients is a massive unmet need,” said Tatum Getty, Founding General Partner at THENA Capital. “Plexāā is building a category-defining platform that can transform care not just in the U.S. but globally. We are proud to support their commercial journey.”
A Vision for the Future of Surgical Care
By working closely with patients, surgeons, and hospital systems, the company is building a technology platform that extends well beyond breast surgery.
According to Plexāā, future development targets include:
- Obstetrics (e.g., C-sections)
- Orthopaedics (e.g., joint replacements)
- General and vascular surgeries
Each application will leverage the same foundation: wearable, digital-first technology designed to reduce complications and improve patient outcomes.
MedTech Leadership with Global Ambitions
Founded by Dr. Saahil Mehta, an experienced physician-entrepreneur, Plexāā brings together a team of clinical, engineering, and operational experts from leading UK institutions.
With bold ambitions to expand across global healthcare markets, the company is building the infrastructure and partnerships needed to scale quickly and effectively.
With its U.S. market launch just ahead, and a Series A fundraising round in the pipeline, Plexāā is well-positioned to become a leader in surgical innovation, particularly in the women’s health and breast reconstruction markets.
